Skip to main content
main-content

Empagliflozin

28-05-2021 | Empagliflozin | News

Empagliflozin gets positive CHMP decision for heart failure

Click through to read more on this announcement

29-03-2021 | Empagliflozin | News

Diuresis ‘not dominant’ mediator of SGLT2 inhibitors’ cardiac benefits

Empagliflozin has similar cardioprotective effects in people with heart failure regardless of whether or not they have recent volume overload, report the EMPEROR-Reduced investigators.

17-02-2021 | Empagliflozin | News

Direct ‘decongestion’ effect shown for empagliflozin in HF

Empagliflozin treatment significantly reduces pulmonary artery blood pressure in patients with heart failure, show findings from the randomized EMBRACE-HF trial.

10-02-2021 | Empagliflozin | News

Adding empagliflozin to closed-loop insulin may reduce need for carbohydrate counting

Among people with type 1 diabetes, adding the SGLT2 inhibitor empagliflozin to an automated insulin delivery system may allow replacement of carbohydrate counting with a simple meal announcement, suggest findings from a pilot randomized trial.

09-02-2021 | Empagliflozin | News

Empagliflozin gains occur on top of neprilysin inhibitor benefits in HF

Findings from EMPEROR-Reduced show that people with heart failure benefit from SGLT2 inhibition even if they are already taking a neprilysin inhibitor.

20-01-2021 | Empagliflozin | News

EMPA-TROPISM: Empagliflozin improves LV remodeling in patients with heart failure

Adding the SGLT2 inhibitor empagliflozin to standard treatment significantly improves left ventricular remodeling among patients with heart failure and reduced ejection fraction but without diabetes, shows a randomized controlled trial.

15-01-2021 | Empagliflozin | News

SGLT2 inhibition may reduce myocardial extracellular volume

Treatment with the SGLT2 inhibitor empagliflozin is associated with a reduction in myocardial extracellular volume among individuals with type 2 diabetes and coronary artery disease, suggests an analysis of data from the EMPA-HEART CardioLink-6 trial.

05-01-2021 | Heart failure | News

Support for fluid reduction mechanism underlying SGLT2 inhibitor cardiorenal benefits

The SGLT2 inhibitor empagliflozin reduces estimated extracellular volume and plasma volume in patients who have heart failure with reduced ejection fraction, shows a randomized trial.

Image Credits